-
Mashup Score: 12Home - Precision Oncology - 23 day(s) ago
This EACCME-accredited webinar will cover chronic kidney disease in cardio-renal-metabolic patients and management in primary care.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Health Care Disparities - 24 day(s) ago
Information and resources about health care disparities from CancerCare.
Source: www.cancercare.orgCategories: General Medicine News, NursingTweet-
Health inequities in #LungCancer mean that some people face barriers to quality health care. Screenings & patient advocates can help. See our free resources that help overcome barriers to care: https://t.co/fILL18u7QE & for anyone affected by lung cancer: https://t.co/RiJMcsJrUK https://t.co/S8aQ2MuLXq
-
-
Mashup Score: 12Home - Precision Oncology - 27 day(s) ago
This EACCME-accredited webinar will cover chronic kidney disease in cardio-renal-metabolic patients and management in primary care.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
Stigma and nihilism are two of the greatest challenges in #lungcancer care. "I can't overemphasize the importance of hope and education and getting the word out that nobody deserves to die of lung cancer," says Michael Gieske, MD. Read his story: https://t.co/JkI3DgNAgZ @mrgieske https://t.co/oBA7m1Pqnl
-
-
Mashup Score: 6California doctor with lung cancer receives first-of-its-kind lung-liver transplant - 1 month(s) ago
Surgeons at Northwestern Medicine Canning Thoracic Institute have performed what is believed to be the first-ever combined lung-liver transplant for a patient with advanced lung cancer, according to medical staff at Northwestern Medicine.The 10-hour surgery took place last September; now 6 months after surgery, medical staff at Northwestern Memorial Hospital say that the patient still has no
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 25Home - Precision Oncology - 1 month(s) ago
This EACCME-accredited webinar will cover chronic kidney disease in cardio-renal-metabolic patients and management in primary care.
Categories: General Medicine News, Onc News and JournalsTweet-
A warm invitation to Biomarker Positive Disease: A personalised approached to selecting Targeted Tx in #LungCancer 🫁& Beyond by our collaborators at @SpringerIME Link: https://t.co/88v2F2PElW with Experts: @HendriksLizza 🇳🇱 @peters_solange 🇨🇭 @DrJaimeLaurel 🇺🇸 Submit your… https://t.co/8S229LVqaq https://t.co/ukaAAGyNsN
-
-
Mashup Score: 23Home - Precision Oncology - 1 month(s) ago
This EACCME-accredited webinar will cover chronic kidney disease in cardio-renal-metabolic patients and management in primary care.
Categories: General Medicine News, Onc News and JournalsTweet-
A warm invitation to Biomarker Positive Disease: A personalised approached to selecting Targeted Tx in #LungCancer 🫁& Beyond by our collaborators at @SpringerIME Link: https://t.co/88v2F2PElW with Experts: @HendriksLizza 🇳🇱 @peters_solange 🇨🇭 @DrJaimeLaurel 🇺🇸 Submit your… https://t.co/8S229LVqaq https://t.co/ukaAAGyNsN
-
-
Mashup Score: 15
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in Europe Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults. This approval by the EC follows the positive recommendation from the Committee for Medicinal Products for Human Use received in February 2024 and was based on results from the Phase 3 KEYNOTE-671 trial. At a median follow-up of 29.8 months (range, 0.4 to 62.0 months), KEYTRUDA plus chemotherapy in the neoadjuvant setting followed by KEYTRUDA as monotherapy after surgical resection significantly
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). In the KEYLYNK-006 trial, KEYTRUDA in combination with chemotherapy followed by KEYTRUDA plus maintenance LYNPARZA did not meet the study’s pre-specified statistical criteria for OS or PFS compared to KEYTRUDA in combination with chemotherapy (pemetrexed plus carboplatin or cisplatin) followed by KEYTRUDA plus maintenance chemotherapy (pemetrexed). The safety profiles of KEYTRUDA and LYNPARZA in this trial were consistent with those observed in previously reported studies for the individual therapies. A full evaluation of the data from this study
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 20Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer - 1 month(s) ago
Targeting the DNA/RNA helicase DHX9 induces the accumulation of double-stranded RNA and R-loops in small cell lung cancer cells, enhancing immunotherapy response and opening new therapeutic opportunities in immunologically ‘cold’ tumors.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
A warm invitation to Biomarker Positive Disease: A personalised approached to selecting Targeted Tx in #LungCancer 🫁& Beyond by our collaborators at @SpringerIME Link: https://t.co/l8smhZsQO1 with Experts: @peters_solange 🇨🇭@DrJaimeLaurel 🇺🇸 and @HendriksLizza 🇳🇱 https://t.co/XHOJ1MYUob